News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Can Bevacizumab Be Recommended in High-Risk Melanoma?

July 24, 2018
Dave Levitan
Article

Treatment of high-risk melanoma with adjuvant bevacizumab following resection improves disease-free survival over standard observation, but not overall survival.

Treatment of high-risk melanoma with adjuvant bevacizumab following surgical resection improves disease-free survival over standard observation, but not overall survival, according to analysis of the AVAST-M trial.

“VEGF is over-expressed in melanoma and high levels have been reported to be associated with poorer outcome,” wrote study authors led by Pippa G. Corrie, MD, of the Cambridge Cancer Centre in the United Kingdom. Bevacizumab targets VEGF, and previously has shown modest activity in advanced melanoma. The new trial evaluated whether bevacizumab can improve outcomes in patients with resected cutaneous melanoma at high risk of recurrence.

The study included a total of 1,343 patients recruited between 2007 and 2012; all had resected stage IIB, IIC, or III melanoma, and were randomized to receive either adjuvant bevacizumab (671 patients) or standard observation (672 patients). Most patients were stage III (73%), and their median age was 56 years; the median follow-up period was 6.4 years. Results were published in Annals of Oncology.

A total of 515 patients (38%) died during the follow-up period, including 38% of those in the bevacizumab group and 39% of those in the observation group. The 5-year overall survival rate was 64% for both groups, and the hazard ratio (HR) for overall survival was 0.98 (95% CI, 0.82–1.16; P = .78). A multivariate analysis found that the treatment was not independently prognostic of overall survival.

The 5-year disease-free survival rate was higher with bevacizumab, at 51% compared with 45% in the observation group, for an HR of 0.85 (95% CI, 0.74–0.99; P = .03). This remained consistent after adjustment for stratification variables. The median disease-free interval was 63 months with bevacizumab, compared with 37 months with observation.

The distant metastasis–free interval was not significantly better with bevacizumab; at 5 years, the rate was 58% compared with 54% with observation, for an HR of 0.91 (95% CI, 0.78–1.07; P = .25).

Most patients in the study completed quality-of-life questionnaires (89%), and these showed no significant differences between the two groups.

Among patients with BRAF mutations, there was a trend toward improved overall survival with bevacizumab, with an HR of 0.80 (95% CI, 0.57–1.13; P = .21). This was not seen in those with BRAF wild-type melanoma.

Based on the study design, the authors concluded that “adjuvant bevacizumab cannot be recommended as a standard adjuvant therapy after resection of melanoma at high risk of recurrence.” However, the findings regarding BRAF mutations, along with other research on the mutations’ connection to response to immune checkpoint inhibition, “raise the hypothesis that combining bevacizumab with adjuvant immune checkpoint inhibitors may benefit high-risk BRAF-mutant melanoma patients.”

Related Videos
Experts on myeloma
Related Content

Atezolizumab Combo Results in Intracranial Activity in BRAFV600+ Melanoma

September 7th 2023

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022

FDA Approves Melphalan Injection in Hepatic-Dominant Uveal Melanoma

August 15th 2023

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022

Cosibelimab Yields Enduring Responses in Metastatic/Advanced Cutaneous SCC

July 31st 2023

Nivolumab Combo Appears Tolerable in Poor Prognosis, Advanced Melanoma

July 9th 2023

Atezolizumab Combo Results in Intracranial Activity in BRAFV600+ Melanoma

September 7th 2023

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022

FDA Approves Melphalan Injection in Hepatic-Dominant Uveal Melanoma

August 15th 2023

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022

Cosibelimab Yields Enduring Responses in Metastatic/Advanced Cutaneous SCC

July 31st 2023

Nivolumab Combo Appears Tolerable in Poor Prognosis, Advanced Melanoma

July 9th 2023

Atezolizumab Combo Results in Intracranial Activity in BRAFV600+ Melanoma

September 7th 2023

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022

FDA Approves Melphalan Injection in Hepatic-Dominant Uveal Melanoma

August 15th 2023

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022

Cosibelimab Yields Enduring Responses in Metastatic/Advanced Cutaneous SCC

July 31st 2023

Nivolumab Combo Appears Tolerable in Poor Prognosis, Advanced Melanoma

July 9th 2023
Related Content
Advertisement

Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.

Atezolizumab Combo Results in Intracranial Activity in BRAFV600+ Melanoma

September 7th 2023
Article

Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.


OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.


Supporting data for the FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study.

FDA Approves Melphalan Injection in Hepatic-Dominant Uveal Melanoma

August 15th 2023
Article

Supporting data for the FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study.


On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.


Cosibelimab Yields Enduring Responses in Metastatic/Advanced Cutaneous SCC | Image Credit: © royalstockphoto - stock.adobe.com.

Cosibelimab Yields Enduring Responses in Metastatic/Advanced Cutaneous SCC

July 31st 2023
Article

Investigators of a phase 1 study evaluating cosibelimab in patients with locally advanced or metastatic cutaneous squamous cell carcinoma plan to share updated results at a future medical conference.


The benefit of nivolumab/ipilimumab plus single-agent nivolumab for unresectable advanced melanoma with poor prognostic characteristics was comparable in all-comers and patients with brain metastases.

Nivolumab Combo Appears Tolerable in Poor Prognosis, Advanced Melanoma

July 9th 2023
Article

The benefit of nivolumab/ipilimumab plus single-agent nivolumab for unresectable advanced melanoma with poor prognostic characteristics was comparable in all-comers and patients with brain metastases.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.